Orexo: Orexo announces positive data for powderbased intranasal vaccine formulated with the AmorphOX technology
Orexo AB (publ.), a Swedish pharmaceutical company, has announced the positive in─vivo proof─of─concept data for a powder─based intranasal vaccine candidate formulated with the AmorphOX technology.
Read full article »
Orexo is a Sweden-based specialty pharmaceutical company that develops and commercial drugs for the treatment of opioid dependence.
Read more